Niagen Bioscience (NAGE) Stock Price
Niagen Bioscience Price
Revenue has compounded at 21.8% per year over the past 17 years to 129.42 M USD. Niagen Bioscience's net margin stands at 13.4%, up from -40.2% several years earlier. Analysts set a median price target of 8.21 USD, implying 232.4% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Niagen Bioscience stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Niagen Bioscience business model & stock analysis
Frequently asked questions about Niagen Bioscience
The business model of Chromadex Corp is focused on the development and commercialization of ingredients and products that promote health, wellness, and longevity. They primarily operate in three segments: Consumer Products, Ingredients, and Analytical Reference Standards. Chromadex Corp aims to discover and develop innovative and scientific-based solutions through its proprietary technologies. They leverage their expertise in natural product chemistry, manufacturing, and research to provide high-quality ingredients to various industries, including pharmaceuticals, dietary supplements, food and beverages, and animal health. Through strategic partnerships and collaborations, Chromadex Corp strives to enhance human health and well-being by delivering differentiated and evidence-backed nutritional and wellness solutions.
Chromadex Corp is primarily active in the industries of nutraceuticals, pharmaceuticals, and food and beverage.
The main competitors of Chromadex Corp in the market include companies like Amarin Corporation, ProPhase Labs, and Natural Alternatives International.
Chromadex Corp is a leading health and wellness company specializing in the discovery, development, and commercialization of innovative ingredients. Established in 1999, Chromadex Corp has grown to become a trusted name in the field, supplying cutting-edge solutions to the dietary supplement, food, beverage, and pharmaceutical industries. With a mission to transform scientific discoveries into life-changing products, Chromadex Corp has a track record of pioneering research and strategic collaborations. As a publicly traded company listed under the symbol CDXC, Chromadex Corp continues to expand its portfolio of patented ingredients and remains committed to delivering high-quality, evidence-based solutions for health-conscious consumers worldwide.
Chromadex Corp, a leading provider of science-based solutions, has achieved several significant milestones. The company successfully developed and commercialized NR (nicotinamide riboside), a breakthrough ingredient in the health industry. Chromadex Corp also established strategic partnerships with major companies like Nestle Health Science and Thorne Research. Additionally, the company has expanded its product portfolio with innovative formulations, including Tru Niagen® – the first and only commercially available form of NR for use in dietary supplements. Chromadex Corp's commitment to scientific research, extensive collaborations, and continuous product innovation have contributed to its impressive growth and recognition in the health and wellness sector.
Chromadex Corp primarily operates in the United States, with headquarters in Irvine, California. The company's presence extends globally, with a focus on various regions including North America, Europe, and Asia. Chromadex Corp is committed to expanding its international footprint and establishing strategic partnerships worldwide to further enhance its market position.
Chromadex Corp represents values of innovation, integrity, and excellence. With a focus on advancing scientific research, Chromadex strives to provide high-quality ingredients and products for the wellness, pharmaceutical, and dietary supplement industries. The company's corporate philosophy revolves around fostering partnerships, conducting rigorous testing, and adhering to industry regulations and ethical standards. By continuously developing and commercializing novel technologies and natural product discoveries, Chromadex aims to contribute to the well-being of individuals and improve the world we live in. With its commitment to quality and forward-thinking approaches, Chromadex Corp stands as a leading player in the industry.
Analysts currently set an average price target of 9.21 USD for the Niagen Bioscience stock (median: 8.21 USD), implying +270.4 % versus the latest price. The consensus is based on 10 analyst ratings.
12 analysts currently rate the Niagen Bioscience stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Niagen Bioscience to generate revenue of 131.69 M USD and earnings per share of 0.12 USD.
Converted at the current exchange rate, the Niagen Bioscience share trades at 2.20 EUR (2.47 USD).
The Niagen Bioscience share (NAGE) is listed on 4 stock exchanges, including: NASDAQ (CDXC), Frankfurt (OCD1.F), München (OCD1.MU), Düsseldorf (OCD1.DU).
Chromadex Corp is a scientifically oriented company that specializes in the development and marketing of dietary supplements. The company is a global leader in the research, development, and manufacturing of innovative and natural products using advanced technologies. The company operates in three divisions: Nutraceuticals, Ingredients, and Analytical Testing. Each division offers unique products and services, allowing Chromadex to target a wide range of customers. The Nutraceutical division focuses on the development, production, and marketing of dietary supplements. The product range includes various complementary products that are of interest to customers seeking a healthy lifestyle. Tru Niagen, an advanced dietary supplement based on natural ingredients with anti-aging and energy-boosting effects, is among these products. Tru Niagen is the result of years of research and is one of the most innovative products on the market. The second division, Ingredients, focuses on supplying high-quality ingredients to customers in the food, beverage, and cosmetics industries. Through the use of advanced technology and collaboration with the company's leading scientists, Chromadex develops high-quality products that help customers expand their product range. Natural ingredients such as plant extracts and complexes are particularly sought after. The Analytical Testing division provides independent and precise analysis of food, dietary supplements, and pharmaceuticals. Chromadex utilizes advanced technology and experienced staff to ensure the quality and safety of products before they are brought to market. Chromadex is a pioneer in the application of chromatography technology to accurately identify and quantify phytonutrients and other important compounds in food and dietary supplements. This method allows for a thorough exploration of potential active ingredients and nutrients, enhancing their effectiveness and function in the food industry or as dietary supplements. Chromadex has always been committed to working based on scientific methodology and best practices in the industry. The company collaborates closely with a variety of researchers and scientists, creating innovations that provide clear benefits to customers. Due to these values, Chromadex is able to remain innovative and competitive in the industry and solidify its position as a market leader in the global dietary supplement market.
The expected revenue of Niagen Bioscience is 131.69 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Niagen Bioscience is 10.31 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Niagen Bioscience is currently 20.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Niagen Bioscience stock.
The price-to-sales ratio (P/S) of Niagen Bioscience is currently 1.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Niagen Bioscience stock.
The Eulerpool Quality Score for Niagen Bioscience is 7/10.
The ISIN of Niagen Bioscience is US1710774076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Niagen Bioscience is A2AG5N. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Niagen Bioscience is NAGE. The ticker symbol is used to trade Niagen Bioscience shares on the stock exchange.
Niagen Bioscience stock
Niagen Bioscience Peer Group
Niagen Bioscience Ticker
Niagen Bioscience FIGI
All fundamentals and in-depth analysis of Niagen Bioscience
Our stock analysis for Niagen Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Niagen Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.